Has David Pfister, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,854 in general payments to David Pfister, MD across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Pfister, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Pfister, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Pfister, MD

Medical Oncology · New York, NYNPI 1316918154

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,854 of the $9,854 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Boehringer Ingelheim Pharma GmbH & Co.kg.

$9,854in general payments, 2019–2025

Across 2 payments — averaging $4927.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim Pharma GmbH & Co.kg$10K

$184,585in research payments, 2019–2025

Across 28 payments — averaging $6592.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$106K
Merck$64K
Novartis$10K
Exelixis Inc.$5K

What the payments were for

Consulting fees$9,854100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim Pharma GmbH & Co.kg	2	$9,854

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GILOTRIF$9,854

How this compares

$9,854 in reported general payments places this provider in the 55th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$44,748

Medicare patients

Services billed

344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LenvimaLenvatinib Mesylate	17	$220,162
Levothyroxine Sodium	29	$251
Ondansetron Hcl	11	$247

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →